Alzheimer’s Disease
-
AbbVie boasts that it will become the largest CNS company in the industry next year!
In the field of biopharmaceuticals, there is no eternal No. 1, only infinite possibilities
-
An asset similar to Roche’s trontinemab | DrugTimes BD Project
If interested in this asset, please feel free to contact the BD team at DrugTimes immediately! Please send an email to BD@drugtimes.cn
-
siRNA Therapeutics Targeting APP for Alzheimer’s Disease (AD) 【Product for Licensing】
If you are interested in this asset or need more information, please kindly contact DrugTimes BD Team at BD@drugtimes.cn, we will present the non-confidential deck to you for review asap. Many thanks!~
-
The development of new drugs for Alzheimer’s disease needs to adopt a holistic approach
“Scientific research always ascends in a spiral development process of negation of n…
-
Lilly’s Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer’s Disease
Congratulations to Eli Lilly and AD patients!
-
【Urgent Request】European and American biotech companies are interested in licensing drugs for PD, AD and other CNS diseases
If interested in this licensing opportunity, please contact DrugTimes BD Team at BD@drugtimes.cn
